| 65.575 -0.905 (-1.36%) | 09-15 13:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 83.16  |
1-year : | 87.59 |
| Resists | First : | 71.2 |
Second : | 75 |
| Pivot price | 69.5 |
|||
| Supports | First : | 65.05 |
Second : | 54.12 |
| MAs | MA(5) : | 66.6 |
MA(20) : | 70.01 |
| MA(100) : | 73.61 |
MA(250) : | 71.98  |
|
| MACD | MACD : | -2 |
Signal : | -1.6 |
| %K %D | K(14,3) : | 5 |
D(3) : | 5.8 |
| RSI | RSI(14): 32.9 |
|||
| 52-week | High : | 90.87 | Low : | 57.74 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PTCT ] has closed above bottom band by 9.1%. Bollinger Bands are 17.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 68.15 - 68.6 | 68.6 - 69.01 |
| Low: | 64.82 - 65.39 | 65.39 - 65.91 |
| Close: | 65.6 - 66.5 | 66.5 - 67.31 |
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Tue, 15 Sep 2026
PTC Therapeutics, Inc. $PTCT Shares Sold by Engineers Gate Manager LP - MarketBeat
Tue, 15 Sep 2026
California State Teachers Retirement System Has $543.82 Million Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Tue, 15 Sep 2026
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Fri, 11 Sep 2026
Director stock sale at PTC Therapeutics (PTCT) ran on a preset 10b5-1 plan - Stock Titan
Fri, 11 Sep 2026
PTCT: SEPHIENCE's rapid global uptake and robust pipeline position the company for sustained growth - TradingView
Fri, 28 Aug 2026
PTC Therapeutics (PTCT) director sells 25K shares under trading plan - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 83 (M) |
| Shares Float | 74 (M) |
| Held by Insiders | 7.3 (%) |
| Held by Institutions | 122.9 (%) |
| Shares Short | 10,220 (K) |
| Shares Short P.Month | 9,830 (K) |
| EPS | -0.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2 |
| Profit Margin | -3.8 % |
| Operating Margin | 41.3 % |
| Return on Assets (ttm) | 2.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 101.5 % |
| Gross Profit (p.s.) | 6.03 |
| Sales Per Share | 12.1 |
| EBITDA (p.s.) | 2.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -287 (M) |
| PE Ratio | -97.86 |
| PEG Ratio | 0 |
| Price to Book value | -32.95 |
| Price to Sales | 5.41 |
| Price to Cash Flow | -179.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|